Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Transcatheter Arterial Chemoembolization Plus 131I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

  • Zhu, Ze-xin (Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University) ;
  • Liao, Ming-heng (Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University) ;
  • Wang, Xiao-xue (Department of Dermatovenereology, West China Hospital, Sichuan University) ;
  • Huang, Ji-wei (Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University)
  • Received : 2016.03.03
  • Accepted : 2016.07.07
  • Published : 2016.11.01
⟨ Previous Next ⟩

Abstract

Objective: The aim of the study was to compare transcatheter arterial chemoembolization (TACE) plus $^{131}I$-labelled metuximab with TACE alone for hepatocellular carcinoma (HCC). Materials and Methods: A comprehensive search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Chinese BioMedical Literature Database with published date from the earliest to February 29th, 2016. No language restrictions were applied, but only prospective randomized controlled trials (RCTs) or non-RCTs were eligible for a full-text review. The primary outcome was the overall survival (OS) and effective rate (the rate of partial atrophy or complete clearance of the tumor lesion). The odds ratios (ORs) were combined using either the fixed-effects model or random-effects model. Results: Eight trials (3 RCTs and 5 non-RCTs) were included, involving a total of 1121 patients. Patients receiving combined therapy of TACE plus $^{131}I$-labelled metuximab showed significant improvement in effective rate {OR = 4.00, (95% confidence interval [CI]: 2.40-6.66), p < 0.001}, 1-year OS (OR = 2.03 [95% CI: 1.55-2.67], p < 0.001) and 2-year OS (OR = 2.57 [95% CI: 1.41-4.66], p = 0.002]. Conclusion: TACE plus $^{131}I$-labelled metuximab is more beneficial for treating advanced HCCs than TACE alone in terms of tumor response and OS. Large, multi-center, and blinded randomized trials are required to confirm these findings.

Keywords

References

  1. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012;62:394-399 https://doi.org/10.3322/caac.21161
  2. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
  4. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235 https://doi.org/10.1007/s00535-005-1566-3
  5. Kamran AU, Liu Y, Li FE, Liu S, Wu JL, Zhang YW. Transcatheter Arterial Chemoembolization with gelatin sponge microparticles treated for BCLC stage B hepatocellular carcinoma: a Single Center Retrospective Study. Medicine (Baltimore) 2015;94:e2154 https://doi.org/10.1097/MD.0000000000002154
  6. Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, et al. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 2012;47:179-186 https://doi.org/10.1007/s00535-011-0475-x
  7. Liu KD, Tang ZY, Bao YM, Lu JZ, Qian F, Yuan AN, et al. Radioimmunotherapy for hepatocellular carcinoma (HCC) using 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 1989;16:319-323 https://doi.org/10.1016/0360-3016(89)90322-2
  8. Duan CL, Hou GH, Liu YP, Liang T, Song J, Han JK, et al. Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma. Tumour Biol 2014;35:12205-12215 https://doi.org/10.1007/s13277-014-2529-1
  9. Fujiwara K, Koyama K, Suga K, Ikemura M, Saito Y, Hino A, et al. A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy. EJNMMI Res 2014;4:29 https://doi.org/10.1186/s13550-014-0029-3
  10. Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006;65:435-444 https://doi.org/10.1016/j.ijrobp.2005.12.034
  11. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007;45:269-276 https://doi.org/10.1002/hep.21465
  12. He Q, Lu WS, Liu Y, Guan YS, Kuang AR. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 2013;19:9104-9110 https://doi.org/10.3748/wjg.v19.i47.9104
  13. Wang GP, Feng XS, Shan TY, Sun JT. Clinical study of transcatheter arterial chemoembolization and hepatic perfusion with 131I metuximad injection in treatment of hepatocellular carcinoma [abstract in English]. Chin J Cancer Prev Treat 2009;16:1022-1024
  14. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: http://www.handbook.cochrane.org. Accessed January 30, 2016
  15. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Int J Surg 2010;8:336-341 https://doi.org/10.1016/j.ijsu.2010.02.007
  16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60 https://doi.org/10.1055/s-0030-1247132
  17. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928 https://doi.org/10.1136/bmj.d5928
  18. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp. Accessed December 20, 2015
  19. Wu L, Yang YF, Ge NJ, Shen SQ, Liang J, Wang Y, et al. Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients. Cancer Biother Radiopharm 2010;25:657-663 https://doi.org/10.1089/cbr.2010.0801
  20. Wu L, Yang YF, Ge NJ, Shen SQ, Liang J, Wang Y, et al. Hepatic artery injection of $^{131}I$-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur J Nucl Med Mol Imaging 2012;39:1306-1315 https://doi.org/10.1007/s00259-012-2145-5
  21. Ma J, Wang JH. 131I-labeled-metuximab plus transarterial chemoembolization in combination therapy for unresectable hepatocellular carcinoma: results from a multicenter phase IV clinical study. Asian Pac J Cancer Prev 2015;16:7441-7447 https://doi.org/10.7314/APJCP.2015.16.17.7441
  22. Guo XD, Sun T, Li SS. The effect of iodine[$^{131}I$] metuximab injection combined with TACE on primary liver cancer [abstract in English]. China J Mod Med 2011;21:1206-1208
  23. Li Z, Zhou JX, Ren JZ, Zhang WJ, Han XW. [Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 2013;21:728-733
  24. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739 https://doi.org/10.1016/S0140-6736(02)08649-X
  25. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-616 https://doi.org/10.1016/S0140-6736(09)60381-0
  26. Kuo YC, Chiu YM, Shih WP, Yu HW, Chen CW, Wong PF, et al. Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensitymodulated radiotherapy and 3-D conformal radiotherapy. Radiat Oncol 2011;6:76 https://doi.org/10.1186/1748-717X-6-76
  27. Zhang Z, Bian H, Feng Q, Mi L, Mo T, Kuang A, et al. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 2006;5:318-322 https://doi.org/10.4161/cbt.5.3.2431
  28. Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003;54:371-389
  29. Li J, Huang Q, Long X, Zhang J, Huang X, Aa J, et al. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/$PPAR{\alpha}$ pathways. J Hepatol 2015;63:1378-1389 https://doi.org/10.1016/j.jhep.2015.07.039
  30. Dai D, Xu W, Liu J, Zhu L, Zhu X, Ma X. Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2013;6:1417-1422 https://doi.org/10.3892/etm.2013.1321
  31. Furtado R, Crawford M, Sandroussi C. Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma. Ann Surg Oncol 2014;21:2700-2707 https://doi.org/10.1245/s10434-014-3511-2
  32. Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and metaanalysis. JAMA Oncol 2015;1:756-765 https://doi.org/10.1001/jamaoncol.2015.2189
  33. Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot FR, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003;17:1247-1261 https://doi.org/10.1046/j.1365-2036.2003.01580.x

Cited by

  1. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928